[References]
[1] J WOODS. Evaluation of new compounds for opioid activity: 1987 annual report.[J]. NIDA research monograph, 1988, 81: 543-590.
[2] SHERIF H. HASSANIEN. In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis[J]. Drug Testing and Analysis, 2020, 12 8: 1212-1221. DOI: 10.1002/dta.2822
[3] NEIL B. VARSHNEYA . Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depression[J]. Pharmacology Biochemistry and Behavior, 2023, 226: Article 173572. DOI: 10.1016/j.pbb.2023.173572
[4] AKIRA MOCHIZUKI. Identification and quantification of mepirapim and acetyl fentanyl in authentic human whole blood and urine samples by GC-MS/MS and LC-MS/MS.[J]. Forensic Toxicology, 2018, 36 1: 81-87. DOI: 10.1007/s11419-017-0384-7
[5] SHIMPEI WATANABE. In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl.[J]. AAPS Journal, 2017, 19 4: 1102-1122. DOI: 10.1208/s12248-017-0070-z |